Predictors of Triptan Response in Pediatric Migraine

详细信息    查看全文

• 作者：Hannah F. Johnson ; BS<sup>asup> ; Peter J. Goadsby ; MD ; PhD<sup>bsup><sup> ; sup><sup>csup> ; Amy A. Gelfand ; MD ; MAS<sup>bsup><sup> ; sup><sup>dsup><sup> ; sup><sup>Amy.gelfand@ucsf.edu" class="auth_mail" title="E-mail the corresponding authorsup>
• 关键词：migraine ; pediatrics ; triptan ; aura ; cranial autonomic symptoms
• 刊名：Pediatric Neurology
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：58
• 期：Complete
• 页码：37-40
• 全文大小：291 K

文摘

Migraine is common in children and adolescents and can be disabling. Being able to predict which patients will respond to triptans based on their clinical phenotype would be helpful. Adult data suggest cranial autonomic symptoms and aura predict triptan response. This study examined clinical predictors of triptan response in pediatric migraineurs.

sSec_2">Methods

spara0015">This chart review study included all patients less than 18 years old with migraine who were seen at the University of California, San Francisco Headache Center in 2014. Univariate χ<sup>2sup> analyses were performed, followed by multivariate logistic regression modeling.

sSec_3">Results

spara0020">Of 127 pediatric migraineurs, 70 (55%) had chronic migraine and 24 (19%) had aura. The majority (55%) had at least one cranial autonomic symptom. Of 65 with triptan outcome data, 47 (73%) benefitted from a triptan. In univariate analyses, triptan benefit was seen in 65% with chronic migraine versus 88% with episodic migraine (P = 0.048), 67% with aura versus 74% without (P = 0.66), and 70% with cranial autonomic symptom versus 74% without (P = 0.76). In a multivariate logistic regression model, chronic migraine, aura, and cranial autonomic symptom were not statistically significant predictors of triptan benefit: chronic migraine: 0.25 (0.06-1.04); aura: 0.65 (0.09-4.45); cranial autonomic symptom: 0.75 (0.22-2.52).

sSec_4">Conclusions

spara0025">In univariate analysis, individuals with chronic migraine were less likely to benefit from triptans. In contrast to what has been documented in adults, cranial autonomic symptoms and aura did not predict triptan response, although our small sample size limited the study's power. Larger pediatric studies are needed, and future pediatric triptan trials should provide response rates stratified by clinical variables such as aura.